ScripsAmerica's RapiMed Product Receives Registration Approval From the Hong Kong Government
February 10 2014 - 8:30AM
ScripsAmerica, Inc. (OTCBB:SCRC) today announced
that the Company has received registration approval for its
RapiMed® Children's Pain Reliever & Fever Reducer from the
Government of Hong Kong.
With the registration process complete, ScripsAmerica is now
free to distribute RapiMed® throughout Hong Kong and the Company is
ready to accept orders from affiliate hospital networks, and
representatives of a major health product retailer with over 2,000
stores and over 500 pharmacies. Because RapiMed® is an
over-the-counter (OTC) medication, it does not require FDA approval
in order to be sold in Hong Kong due to the fact that its
manufacturer is CGMP (Current Good Manufacturing Practices)
certified. With this certification, RapiMed®'s manufacturer needs
only to follow the monograph process for the product's active
ingredient. A monograph defines the safety, effectiveness, and
labeling of all marketing OTC active ingredients and once a final
monograph is completed, companies can make and market an OTC
product without the need for FDA pre-approval.
Bob Schneiderman, CEO of ScripsAmerica, states "ScripsAmerica is
very excited to announce RapiMed's registration approval by the
Government of Hong Kong to allow the distribution of our children's
pain reliever. Now the company can focus all of its efforts on
finalizing distribution agreements with a large affiliate hospital
network and major health product retailer to sell our product
throughout Greater Asia."
"We believe that our product's unique and innovative rapid melt
technology will lead to tremendous success in the Chinese OTC
pharmaceutical market which will lead to expansion into other
international markets, including new OTC drugs using our
proprietary RapiMed formulation. This is a major milestone for
ScripsAmerica that we believe is the beginning of significant
revenue growth and increased shareholder value," Schneiderman
continued.
About ScripsAmerica, Inc.
ScripsAmerica, Inc. is a supplier of prescription, OTC and
nutraceutical drugs, delivering pharmaceutical products to a wide
range of end users across the health care industry. End users
include retail pharmacies, hospitals, long-term care facilities and
government and home care agencies. For more information, visit
www.ScripsAmerica.com.
Safe Harbor Statement This release includes
forward-looking statements, which are based on certain assumptions
and reflects management's current expectations. These
forward-looking statements are subject to a number of risks and
uncertainties that could cause actual results or events to differ
materially from current expectations. Some of these factors
include: general global economic conditions; general industry and
market conditions, sector changes and growth rates; uncertainty as
to whether our strategies and business plans will yield the
expected benefits; increasing competition; availability and cost of
capital; the ability to identify and develop and achieve commercial
success; the level of expenditures necessary to maintain and
improve the quality of services; changes in the economy; changes in
laws and regulations, including codes and standards, intellectual
property rights, and tax matters; or other matters not anticipated;
our ability to secure and maintain strategic relationships and
distribution agreements. The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
CONTACT: 888-959-7095
ir@sealpointconsulting.com
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Mar 2024 to Apr 2024
ScripsAmerica (CE) (USOTC:SCRCQ)
Historical Stock Chart
From Apr 2023 to Apr 2024